---
title: "Ionis Pharmaceuticals tumbles 9% as Phase 3 trial fails endpoint"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292350378.md"
description: "Ionis Pharmaceuticals (IONS.US) tumbled 9% to $58.62 after its Phase 3 trial failed to meet the primary endpoint."
datetime: "2026-07-10T18:52:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292350378.md)
  - [en](https://longbridge.com/en/news/292350378.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292350378.md)
---

# Ionis Pharmaceuticals tumbles 9% as Phase 3 trial fails endpoint

Ionis 制药 (IONS.US) 盘中跌**8.79%**，现报**58.62**美元。

公司 Cardio-Ttransform 三期临床试验未能达到主要疗效终点，股价延续前一交易日跌势。该试验评估 Eplontersen 联合标准护理治疗 ATTR-CM 的效果，结果显示与单独使用标准护理相比无显著获益。分析认为这一结果利好竞争对手 Alnylam 的 Amvuttra 和辉瑞的 Tafamidis。

### Related Stocks

- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)

## Related News & Research

- [Ionis Q2 adjusted operating loss narrows](https://longbridge.com/en/news/294198021.md)
- [Ionis director Michael R. Hayden reports acquisition of 20,000 common shares worth $1,059,000](https://longbridge.com/en/news/294553943.md)
- [Entropy Technologies LP Makes New $2.04 Million Investment in Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/293897817.md)
- [Ionis announces Dr. Frank Bennett, chief scientific officer, to retire | IONS Stock News](https://longbridge.com/en/news/294199095.md)
- [Stempoint Capital LP Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS](https://longbridge.com/en/news/294341144.md)